Author: eqs

Major Milestone CF PHARMTECH, INC. 2652.HK Announces IND Acceptance for PAH New Drug with a Globally Innovative Improved Mechanism, Marking Another Milestone for Its Precision Drug Delivery Platform

EQS via SeaPRwire.com / 16/03/2026 / 18:08 UTC+8 Focused on developing high-value inhalation therapies for pulmonary hypertension (PAH and PH-ILD), with clinical potential to expand into pulmonary fibrosis indications (PF-ILD, including IPF and PPF). Suzhou, China, March 13, 2026 —

More